by Robert Hayes Posted on February 17, 2023February 17, 2023 Wilmington’s Charles River Laboratories & Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration Read More
by Robert Hayes Posted on February 2, 2023February 3, 2023 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires SAMDI Tech For $50 Million Read More
by Robert Hayes Posted on December 9, 2022December 9, 2022 Wilmington’s Charles River Labs Adds Craig Thompson, M.D. To Board of Directors Read More
by Robert Hayes Posted on October 19, 2022October 19, 2022 BUSINESS BRIEF: Wilmington’s Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership Read More
by Robert Hayes Posted on June 28, 2022June 28, 2022 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Announces Opening of U.K. Manufacturing Facility Read More
by Robert Hayes Posted on April 10, 2022April 10, 2022 Wilmington’s Charles River Laboratories Acquires Explora BioLabs Read More
by Robert Hayes Posted on March 28, 2022March 28, 2022 Wilmington’s Charles River Laboratories To Appoint Flavia H. Pease As Chief Financial Officer Read More
by Robert Hayes Posted on January 26, 2022January 27, 2022 BUSINESS BRIEF: Wilmington’s Charles River & Valo Health Announce Strategic Partnership To Provide Access To AI-Enabled Drug Discovery Solutions Read More
by Robert Hayes Posted on November 11, 2021November 12, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Promotes Birgit Girshick To Chief Operating Officer Read More
by Robert Hayes Posted on July 3, 2021July 3, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires Vigene Biosciences For $292.5 Million Read More
Wilmington Apple 
You must be logged in to post a comment.